Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Irene Straßl(Krankenhaus der Elisabethinen), Maria‐Theresa Krauth(Medical University of Vienna), Nina Worel(Medical University of Vienna), Eduard Schulz(Medical University of Graz), Axel Schulenburg(Medical University of Vienna), Sigrid Machherndl‐Spandl(Krankenhaus der Elisabethinen), Michael Leisch(Paracelsus Medical University), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Normann Steiner(Innsbruck Medical University), Werner Rabitsch(Medical University of Vienna), Wolfgang Willenbacher(Universität Innsbruck), Annkristin Heine(Medical University of Graz), Thomas Melchardt(Paracelsus Medical University), Johannes Clausen(Johannes Kepler University of Linz), Dagmar Wipplinger(Krankenhaus der Elisabethinen), Peter Neumeister(Medical University of Graz), Holger Rumpold(Johannes Kepler University of Linz), Petra Pichler-Izmir(Universitätsklinikum St. Pölten), Lina Zoe Ruesing(Medical University of Vienna), Olga Saini(Johannes Kepler University of Linz), Theresa Lentner(Universitätsklinikum St. Pölten), Alexander Nikoloudis(Johannes Kepler University of Linz), Dominik Wolf(Innsbruck Medical University), Hermine Agis(Medical University of Vienna)
Cited by 0
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540